AVTX vs. SLGL, VINC, GLYC, OCX, FBIO, RPHM, LEXX, MRKR, LTRN, and KZR
Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Sol-Gel Technologies (SLGL), Vincerx Pharma (VINC), GlycoMimetics (GLYC), OncoCyte (OCX), Fortress Biotech (FBIO), Reneo Pharmaceuticals (RPHM), Lexaria Bioscience (LEXX), Marker Therapeutics (MRKR), Lantern Pharma (LTRN), and Kezar Life Sciences (KZR). These companies are all part of the "medical" sector.
Sol-Gel Technologies (NASDAQ:SLGL) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
Sol-Gel Technologies presently has a consensus target price of $6.50, indicating a potential upside of 1,197.41%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Avalo Therapeutics.
Sol-Gel Technologies has higher revenue and earnings than Avalo Therapeutics.
In the previous week, Avalo Therapeutics had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 4 mentions for Avalo Therapeutics and 3 mentions for Sol-Gel Technologies. Avalo Therapeutics' average media sentiment score of 1.22 beat Sol-Gel Technologies' score of 1.14 indicating that Sol-Gel Technologies is being referred to more favorably in the media.
26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 0.3% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Sol-Gel Technologies received 143 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 63.25% of users gave Sol-Gel Technologies an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
Sol-Gel Technologies has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Sol-Gel Technologies has a net margin of -1,329.13% compared to Sol-Gel Technologies' net margin of -1,639.50%. Avalo Therapeutics' return on equity of -56.20% beat Sol-Gel Technologies' return on equity.
Summary
Sol-Gel Technologies beats Avalo Therapeutics on 14 of the 16 factors compared between the two stocks.
Get Avalo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalo Therapeutics Competitors List
Related Companies and Tools
